Cognition Therapeutics (NASDAQ:CGTX) Receives “Buy” Rating from HC Wainwright

Cognition Therapeutics (NASDAQ:CGTX)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $3.00 price objective on the stock. HC Wainwright’s price target would suggest a potential upside of 97.37% from the company’s current price.

A number of other research firms have also recently issued reports on CGTX. Wall Street Zen upgraded shares of Cognition Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cognition Therapeutics in a report on Wednesday, October 8th. Finally, Chardan Capital reiterated a “buy” rating and issued a $4.00 price target on shares of Cognition Therapeutics in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Cognition Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $2.83.

Cognition Therapeutics Price Performance

Shares of CGTX stock opened at $1.52 on Wednesday. Cognition Therapeutics has a twelve month low of $0.22 and a twelve month high of $3.83. The company has a market cap of $134.17 million, a P/E ratio of -3.17 and a beta of 1.23. The business has a fifty day simple moving average of $1.66 and a 200 day simple moving average of $1.14.

Cognition Therapeutics (NASDAQ:CGTX) last released its earnings results on Thursday, November 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. As a group, equities research analysts anticipate that Cognition Therapeutics will post -0.8 earnings per share for the current fiscal year.

Institutional Trading of Cognition Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. DAVENPORT & Co LLC bought a new position in Cognition Therapeutics during the 3rd quarter worth $3,631,000. Vanguard Group Inc. raised its position in shares of Cognition Therapeutics by 105.6% during the third quarter. Vanguard Group Inc. now owns 2,681,613 shares of the company’s stock worth $3,620,000 after acquiring an additional 1,377,263 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Cognition Therapeutics by 814.1% during the first quarter. Acadian Asset Management LLC now owns 1,007,586 shares of the company’s stock worth $422,000 after acquiring an additional 897,353 shares during the last quarter. Chescapmanager LLC boosted its holdings in Cognition Therapeutics by 98.1% in the third quarter. Chescapmanager LLC now owns 997,029 shares of the company’s stock valued at $1,346,000 after acquiring an additional 493,770 shares during the last quarter. Finally, Millennium Management LLC acquired a new stake in Cognition Therapeutics during the 3rd quarter valued at approximately $757,000. 43.35% of the stock is currently owned by institutional investors and hedge funds.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.